Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 15:12:05 UTC |
---|
Update Date | 2022-03-07 02:49:16 UTC |
---|
HMDB ID | HMDB0002710 |
---|
Secondary Accession Numbers | - HMDB0005078
- HMDB02710
- HMDB05078
|
---|
Metabolite Identification |
---|
Common Name | Prostaglandin J2 |
---|
Description | Prostaglandin J2 (PGJ2) is an endogenous product of inflammation in humans. It induces neuronal death and the accumulation of ubiquitinated proteins into distinct aggregates. It may play a role in neurodegenerative disorders inducing a chain of events that culminates in neuronal cell death. An altered expression of enzymes in PGJ2 synthesis may represent a novel pathogenic mechanism in human obesity. The peroxisome proliferator-activated receptor gamma (PPARγ) has a fundamental role in glucose homeostasis and adipocyte differentiation. Besides linoleate, linolenate and arachidonate, the most notable PPAR ligand is 15-deoxy-delta12-14-prostaglandin J2, a natural derivative of prostaglandin D2 and PGJ2. It is therefore plausible that the production of 15d-PGJ2 within adipose tissue may act as an endogenous mediator of adipocyte differentiation. PGJ2 disrupts the cytoskeleton in neuronal cells. This cyclopentenone prostaglandin triggered endoplasmic reticulum (ER) collapse and the redistribution of ER proteins, such as calnexin and catechol-O-methyltransferase, into a large centrosomal aggregate containing ubiquitinated proteins and alpha-synuclein. The PGJ2-dependent cytoskeletal rearrangement paralleled the development of the large centrosomal aggregate. Supporting a mechanism by which, upon PGJ2 treatment, cytoskeleton/ER collapse coincides with the relocation of ER proteins, other potentially neighboring proteins, and ubiquitinated proteins into centrosomal aggregates. Development of these large perinuclear aggregates is associated with disruption of the microtubule/ER network. This aberrant protein deposition, triggered by a product of inflammation, may be common to other compounds that disrupt microtubules and induce protein aggregation, such as MPP+ and rotenone, found to be associated with neurodegeneration. Many neurodegenerative disorders, such as Parkinson disease, exhibit inclusion bodies containing ubiquitinated proteins. Concentrations of PGJ2 in biofluids have not been established, since this prostaglandin is further metabolized into delta12-PGJ2, and 15-deoxy-delta12,14-PGJ2. (PMID: 16737963 , 16842938 , 16774923 )Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-13+/t16-,17-,18+/m0/s1 |
---|
Synonyms | Value | Source |
---|
9-Deoxy-delta-9-PGD2 | ChEBI | 9-Deoxy-delta-9-prostaglandin D2 | ChEBI | PGJ2 | ChEBI | 9-Deoxy-δ-9-PGD2 | Generator | 9-Deoxy-δ-9-prostaglandin D2 | Generator | 11-oxo-15S-Hydroxy-5Z,8Z,13E-prostatrienoate | HMDB | 11-oxo-15S-Hydroxy-5Z,8Z,13E-prostatrienoic acid | HMDB |
|
---|
Chemical Formula | C20H30O4 |
---|
Average Molecular Weight | 334.4498 |
---|
Monoisotopic Molecular Weight | 334.214409448 |
---|
IUPAC Name | (5Z)-7-[(1S,5R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid |
---|
Traditional Name | prostaglandin J2 |
---|
CAS Registry Number | 60203-57-8 |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O |
---|
InChI Identifier | InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-13+/t16-,17-,18+/m0/s1 |
---|
InChI Key | UQOQENZZLBSFKO-POPPZSFYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Prostaglandins and related compounds |
---|
Alternative Parents | |
---|
Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Hydroxy fatty acid
- Fatty acid
- Unsaturated fatty acid
- Ketone
- Cyclic ketone
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Carbonyl group
- Organooxygen compound
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Prostaglandin J2,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2796.6 | Semi standard non polar | 33892256 | Prostaglandin J2,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2737.8 | Semi standard non polar | 33892256 | Prostaglandin J2,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O | 2885.5 | Semi standard non polar | 33892256 | Prostaglandin J2,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2754.9 | Semi standard non polar | 33892256 | Prostaglandin J2,2TMS,isomer #2 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2911.3 | Semi standard non polar | 33892256 | Prostaglandin J2,2TMS,isomer #3 | CCCCC[C@H](O)/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2858.9 | Semi standard non polar | 33892256 | Prostaglandin J2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2887.8 | Semi standard non polar | 33892256 | Prostaglandin J2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2741.4 | Standard non polar | 33892256 | Prostaglandin J2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3087.8 | Standard polar | 33892256 | Prostaglandin J2,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3039.4 | Semi standard non polar | 33892256 | Prostaglandin J2,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 2983.3 | Semi standard non polar | 33892256 | Prostaglandin J2,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O | 3112.0 | Semi standard non polar | 33892256 | Prostaglandin J2,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C(=O)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3241.2 | Semi standard non polar | 33892256 | Prostaglandin J2,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3344.9 | Semi standard non polar | 33892256 | Prostaglandin J2,2TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3326.9 | Semi standard non polar | 33892256 | Prostaglandin J2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3570.7 | Semi standard non polar | 33892256 | Prostaglandin J2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3289.9 | Standard non polar | 33892256 | Prostaglandin J2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/C1=C(O[Si](C)(C)C(C)(C)C)C=C[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3274.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin J2 GC-MS (Non-derivatized) - 70eV, Positive | splash10-067u-5392000000-9b45d3f37955c67682bf | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin J2 GC-MS (2 TMS) - 70eV, Positive | splash10-00bi-9212200000-d9dcb4c0bb23a56c81d0 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin J2 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin J2 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-01b9-0089000000-78fdf4aa71747b22d9f5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-00xr-0097000000-d507bda3b27e80eb9966 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-00di-0094000000-f6f67078fe3ecda59341 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-00di-0091000000-240dba66bc1f4401b0c1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-00di-0090000000-1cb619054c8aa83a868d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-0fk9-0190000000-505725a881b9d2e93ec9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-0uk9-0290000000-de982b17f44086e4d4ae | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-0udi-0590000000-8f4c01a7293ad0cf7235 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Prostaglandin J2 LC-ESI-QIT , negative-QTOF | splash10-0uka-0950000000-219ff8b09fa3a4091f0e | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 10V, Positive-QTOF | splash10-014j-0069000000-a381e76c384ef4a00dd2 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 20V, Positive-QTOF | splash10-01bj-2592000000-31c78f2cc310297d596e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 40V, Positive-QTOF | splash10-05to-9320000000-0ffe9cf3d89d02767050 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 10V, Negative-QTOF | splash10-001i-0019000000-09381487459f4a98eaef | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 20V, Negative-QTOF | splash10-0159-2159000000-e8aa48903843629c8575 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 40V, Negative-QTOF | splash10-0a4i-9330000000-ccd52bfaf256d7ac2024 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 10V, Negative-QTOF | splash10-00lr-0009000000-3a01c9a41ab9915ff411 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 20V, Negative-QTOF | splash10-00si-0297000000-26f532b6f59ff7845c98 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 40V, Negative-QTOF | splash10-0911-7930000000-05c866b3a6adf47ee471 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 10V, Positive-QTOF | splash10-00kk-0596000000-3753a6f26d8178114c13 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 20V, Positive-QTOF | splash10-05mt-5971000000-9fb5b5e59d1fca621a86 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin J2 40V, Positive-QTOF | splash10-0a4i-9810000000-3362a9f0c438d0c276a7 | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
General References | - Ogburn KD, Bottiglieri T, Wang Z, Figueiredo-Pereira ME: Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol Dis. 2006 May;22(2):294-301. Epub 2006 Jan 5. [PubMed:16406650 ]
- Fukushima S, Takeuchi Y, Kishimoto S, Yamashita S, Uetsuki K, Shirakawa S, Suzuki M, Furuta K, Noyori R, Sasaki H, Kikuchi Y, Kita T, Yamori T, Sawada J, Kojima M, Hazato A, Kurozumi S, Fukushima M: Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-deoxy-Delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826). Anticancer Drugs. 2001 Mar;12(3):221-34. [PubMed:11290870 ]
- Coyle AT, O'Keeffe MB, Kinsella BT: 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J. 2005 Sep;272(18):4754-73. [PubMed:16156795 ]
- Wang Z, Aris VM, Ogburn KD, Soteropoulos P, Figueiredo-Pereira ME: Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells. J Biol Chem. 2006 Jul 28;281(30):21377-86. Epub 2006 May 30. [PubMed:16737963 ]
- Quinkler M, Bujalska IJ, Tomlinson JW, Smith DM, Stewart PM: Depot-specific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis. Gene. 2006 Oct 1;380(2):137-43. Epub 2006 Jun 10. [PubMed:16842938 ]
- Ogburn KD, Figueiredo-Pereira ME: Cytoskeleton/endoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates. J Biol Chem. 2006 Aug 11;281(32):23274-84. Epub 2006 Jun 14. [PubMed:16774923 ]
|
---|